Taysha Gene Therapies Inc... (TSHA)
| Bid | 1.19 |
| Market Cap | 260.44M |
| Revenue (ttm) | 8.33M |
| Net Income (ttm) | -89.3M |
| EPS (ttm) | -0.36 |
| PE Ratio (ttm) | -3.53 |
| Forward PE | -5.79 |
| Analyst | Buy |
| Ask | 1.5 |
| Volume | 678,547 |
| Avg. Volume (20D) | 2,121,819 |
| Open | 1.27 |
| Previous Close | 1.28 |
| Day's Range | 1.24 - 1.35 |
| 52-Week Range | 1.05 - 4.32 |
| Beta | 0.94 |
About TSHA
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of ...
Analyst Forecast
According to 8 analyst ratings, the average rating for TSHA stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 451.14% from the latest price.
Stock Forecasts
1 month ago · seekingalpha.com
Taysha Gene Therapies, Inc. (TSHA) Q4 2024 Earnings Call TranscriptTaysha Gene Therapies, Inc. (NASDAQ:TSHA ) Q4 2024 Earnings Conference Call February 26, 2025 8:30 AM ET Company Participants Hayleigh Collins - Director & Head of Investor Relations Sean Nolan - Chie...
